Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed

Amarin (Nasdaq: AMRN ) announced today that the U.S. Food and Drug Administration (FDA) notified the company last night that the FDA does not expect to take action on Amarin's supplemental new drug application (sNDA) for the proposed ANCHOR indication labeling expansion for Vascepa® (icosapent ethyl) capsules on